Evidence map›Paper›PMID 42856803›Full record

ArticleFrontiers in pharmacology2026

Interpretable machine learning classifies β-lactamase subclasses and prioritizes boundary variants for antimicrobial resistance surveillance.

Rahul Kaushik, Suyong Re

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rahul KaushikLaboratory of In-silico Design, Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Osaka, Japan.
Suyong ReLaboratory of In-silico Design, Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Antimicrobial resistance is a major global health threat, and β-lactamase-mediated inactivation of β-lactam antibiotics remains a leading cause of treatment failure. Rapid identification of emerging β-lactamase variants and improved understanding of their functional diversity are therefore essential for resistance surveillance and therapeutic development. Methods: Here, we developed an interpretable machine learning framework to classify major Class A β-lactamase subclasses (TEM, SHV, and CTX-M) and distinguish them from non-β-lactamase hydrolases using multidimensional protein descriptors. Descriptors based on sequence composition, physicochemical properties, residue accessibility, and structural topology were evaluated to identify a minimal panel of 30 descriptors while preserving biological interpretability. Results: The selected descriptors provided strong discriminatory power and were linked to steric environment, hydrophobicity, flexibility, solvent exposure, and residue interaction patterns, consistent with roles in substrate recognition and catalysis. Projection into reduced descriptor space identified transitional variants near subclass boundaries, including CTX-M/SHV convergence zones and non-β-lactamase hydrolases with partial β-lactamase-like signatures. Representative case studies indicated that some apparent misclassifications may reflect annotation inconsistencies, scaffold convergence, or early adaptive trajectories, highlighting candidates for experimental follow-up. External validation using 271 independent proteins annotated as non-β-lactamase hydrolases demonstrated 96.95% specificity, with only limited false-positive assignments. Most incorrect classifications showed weak statistical support, indicating that confidence filtering could further improve screening performance. Discussion: Overall, this study demonstrates that compact descriptor-based models can provide accurate and interpretable classification of β-lactamase-related proteins while identifying emerging boundary variants relevant to antimicrobial resistance surveillance. The framework offers a scalable approach for protein annotation, monitoring resistance evolution, and supporting future inhibitor development.

Indexed as

antimicrobial resistancecomputational pharmacologydrug resistance mechanismsexplainable machine learningresistance surveillanceβ-lactamase

Identifiers

PMID42856803
PMCPMC13649423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.